Skip to content

Sarepta Therapeutics’ President And CEO Chris Garabedian On Eteplirsen: YouTube Video

October 25, 2012

       On October 23, 2012, Parent Project Muscular Dystrophy (PPMD) hosts a webinar with Chris Garabedian, President and CEO of Sarepta Therapeutics. Mr. Garabedian presents Phase IIb extension study data from the 48-week dystrophin & 6-minute walk test for Eteplirsen for treatment of Duchenne Muscular Dystrophy (DMD). Also, next steps for the Eteplirsen program is presented. 

Copyright  © 2012-2013, Ann-Teresa Cusenza and Orphan Druganaut Blog.  All rights reserved.

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: